Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

CJC-1295 with DAC: mechanism of action

CJC-1295 with DAC is a GHRH analogue bearing a Drug Affinity Complex that extends its plasma residence time; this page sets out its mechanism, the receptor family it acts on, and what the published evidence does and does

peptides-pro Editorial

CJC-1295 with DAC (also written CJC-1295 DAC, and referred to in the clinical literature as CJC 1295) is a growth hormone-releasing hormone (GHRH) analogue — a synthetic peptide in the same mechanistic class as sermorelin and tesamorelin — modified by the addition of a Drug Affinity Complex (DAC) intended to prolong its presence in circulation [1]. It is handled in the literature as a research compound rather than an approved therapeutic, and it appears in reviews of performance-enhancing peptides marketed as research chemicals [1]. The evidence block used for this page does not supply a sequence, molecular formula, or molecular weight for the molecule, so none is stated here.

The pathway the work centres on is the GH–IGF-1 axis: GHRH analogues act at the GHRH receptor on pituitary somatotrophs, and the downstream readouts of interest are growth hormone release and insulin-like growth factor-1 [1].

Research Studies

CJC-1295 with DAC and the GH–IGF-1 axis

CJC-1295 with DAC is grouped with GHRH analogues in a review of performance-enhancing peptides that modulate the growth hormone–insulin-like growth factor-1 axis. That review lists CJC-1295 with DAC alongside CJC-1295 without DAC, sermorelin, and tesamorelin as the GHRH analogues most commonly encountered both in clinical practice and in online self-administration protocols, and separates them from the growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), from the GH fragment AOD9604 (hGH 176-191), and from IGF-1 analogues [1]. The mechanistic distinction drawn in that source is class-level: GHRH analogues act on the GHRH receptor arm of the axis, while secretagogues act through a separate receptor family. The review is a survey of the landscape rather than a primary mechanistic study, so the receptor-level detail it supports is limited to that classification.

CJC-1295 with DAC and the Drug Affinity Complex

The DAC designation is part of the compound's formal name as it appears in the literature — CJC-1295 with Drug Affinity Complex [1]. The evidence block does not describe the chemistry of the DAC moiety, its binding target, or the magnitude of any half-life extension, and no such detail is asserted here. What the naming convention establishes is that the literature treats CJC-1295 with DAC and CJC-1295 without DAC as two distinct entries within the same GHRH analogue class [1]. Any claim about how the DAC alters pharmacokinetics would require a source that the evidence block does not contain.

CJC-1295 with DAC and human trial design

The one human study design captured in the evidence block is a multicentre, randomized, placebo-controlled, double-blind Phase 2 study of CJC 1295 in patients with HIV-associated visceral obesity. Participants were treated for a total of 12 weeks, with a 6-week follow-up period after treatment ended, and were randomly assigned to low-dose CJC 1295, high-dose CJC 1295, or placebo. The stated objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability in that population [6]. This is a registered study record describing design and objectives; the evidence block does not report its results, and no outcome is claimed here.

CJC-1295 with DAC and the population studied

The population in that registered trial is adults with HIV-associated visceral obesity [6]. That matters for how the record should be read: the design is specific to a clinical population with a defined condition, and the evidence block contains no trial record for healthy volunteers, athletes, or any other group. Where a page describes an effect, the population in which it was observed has to be named — here, the only named population is the HIV-associated visceral obesity cohort in the Phase 2 record [6].

CJC-1295 with DAC and the peptide class in sports medicine

Reviews of peptide therapies in sports medicine place compounds of this type within a broader category of short amino-acid chains that occupy a pharmacological niche between small-molecule drugs and large proteins, and note that use in that setting is expanding in response to patient demand for accelerated injury recovery and performance enhancement [4][5]. The same body of work describes a parallel gray market of unapproved compounds operating largely outside regulatory oversight, distinct from peptide drugs that have gone through a formal approval process evaluating safety and efficacy [4][5]. CJC-1295 with DAC is not named in those abstracts; the relevance is class-level, and the mechanism claims they support are about peptides as a category rather than about this molecule specifically.

CJC-1295 with DAC and product quality data

An evaluation of research-grade peptides marketed directly to consumers used a large, publicly available independent testing dataset to assess purity, measured abundance, and endotoxin burden, and to compare cost against compounded and FDA-approved alternatives; the study drew on a total of 6,441 products [2]. The framing of that work is that peptides are a rapidly expanding drug class with a parallel, largely unregulated gray market selling preparations directly to consumers for self-administration, and that patients self-administer these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement [2]. The finding relevant to a mechanism page is analytical rather than pharmacological: variability in purity and measured abundance was extensive across the products tested [2]. The evidence block does not break the dataset down by compound, so no figure is attributed to CJC-1295 with DAC.

CJC-1295 with DAC and gerontological peptide review

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles for peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus, and regulatory databases including the FDA and WADA [3]. Its stated framing is that peptide therapeutics target hallmarks of aging such as metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline [3]. The abstract does not name CJC-1295 with DAC, and the evidence block does not attribute any specific finding to it from that review. It is included here because it establishes the review-level context in which GH-axis peptides are discussed, not because it reports a result for this compound.

CJC-1295 with DAC and evidence quality in the wider literature

Several reviews in the evidence block converge on the same observation about the evidence base for injectable and supplemental peptides promoted for recovery and performance: clinical adoption has outpaced high-quality evidence and regulatory consensus [8], and these products are often perceived as low risk despite the absence of efficacy or safety data [7]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides marketed as more selective and ostensibly safer alternatives, a category that includes growth hormone secretagogues such as ipamorelin [10]. These are reference-only sources and are cited here as context for how the field characterises its own evidence base; they are not studies of CJC-1295 with DAC, and no finding is attributed to this compound from them.

CJC-1295 with DAC and what the evidence does not establish

Across the sources available, the mechanistic claim that can be made about CJC-1295 with DAC is a class-level one: it is a GHRH analogue, and GHRH analogues act within the GH–IGF-1 axis [1]. The evidence block contains no in vitro receptor-binding data, no animal-model results, and no reported human outcomes for this compound. The Phase 2 record describes a design and objectives in a specific population and reports no results [6]. Where this page has described variability in purity and abundance, that finding comes from analytical testing of gray-market research peptides as a category [2], not from a study of this molecule. Statements about the wider peptide field — evidence quality, regulatory status, doping context — come from reviews of that field [3][4][5][7][8][10] and should not be read as findings about CJC-1295 with DAC.

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp